Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma

Leukemia and Lymphoma

Volumn 48, Issue 11, 2007, Pages 2110-2120

  Shimoni, Avichai ^a   Nagler, Arnon ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Iodine 131 tositumomab; Non Hodgkin lymphoma; Radioimmunotherapy; Stem cell transplantation; Yttrium 90 ibritumomab tiuxetan

Indexed keywords

CARMUSTINE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; IBRITUMOMAB TIUXETAN; MELPHALAN; RITUXIMAB; TOSITUMOMAB I 131;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CARDIOPULMONARY INSUFFICIENCY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONCENTRATION RESPONSE; DISEASE FREE SURVIVAL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; DRUG URINE LEVEL; HISTOPATHOLOGY; HUMAN; LIVER TOXICITY; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE ORGAN FAILURE; MYELODYSPLASIA; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION HAZARD; RADIOIMMUNOTHERAPY; RADIOISOTOPE THERAPY; RADIOSENSITIVITY; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, B-CELL; NEOPLASM INVASIVENESS; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 36048982278     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701573273     Document Type: Review

References (59)

1. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H. and Bron, D. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med, 333, pp. 1540-1545.
2. Philip, T., Armitage, J. O., Spitzer, G., Chauvin, F., Jagannath, S. and Cahn, J. Y. (1987) High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med, 316, pp. 1493-1498.
3. Vose, J. M., Zhang, M. J., Rowlings, P. A., Lazarus, H. M., Bolwell, B. J. and Freytes, C. O. (2001) Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol, 19, pp. 406-413.
4. Shipp, M. A., Abeloff, M. D., Antman, K. H., Carroll, G., Hagenbeek, A. and Loeffler, M. (1999) International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: Report of the jury. J Clin Oncol, 17, pp. 423-429.
5. Hahn, T., Wolff, S. N., Czuczman, M., Fisher, R. I., Lazarus, H. M. and Vose, J. (2001) The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: An evidence-based review. Biol Blood Marrow Transplant, 7, pp. 308-331.
6. Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H. and Bouabdallah, R. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346, pp. 235-242.
7. Hess, G., Flohr, T. and Derigs, H. G. (2002) Rituximab as in vivo purging agent in autologous stem cell transplantation for relapsed B-NHL. Ann Hematol, 81, pp. S54-S55.
8. Flinn, I. W., O'Donnell, P. V., Goodrich, A., Vogelsang, G., Abrams, R. and Noga, S. (2000) Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant, 6, pp. 628-632.
9. Khouri, I., Saliba, R. M., Hosing, C., Okoroji, G. J., Acholonu, S. and Anderlini, P. (2005) Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol, 23, pp. 2240-2247.
10. Shimoni, A., Hardan, I., Avigdor, A., Yeshurun, M., Raanani, P. and Ben-Bassat, I. (2003) Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. Br J Haematol, 122, pp. 457-464.
11. Horwitz, S. M., Negrin, R. S., Blume, K. G., Breslin, S., Stuart, M. J. and Stockerl-Goldstein, K. E. (2004) Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood, 103, pp. 777-783.
12. Brown, J. R., Yeckes, H., Friedberg, J. W., Neuberg, D., Kim, H. and Nadler, L. M. (2005) Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol, 23, pp. 2208-2214.
13. Sebban, C., Mounier, N., Brousse, N., Belanger, C., Brice, P. and Haioun, C. (2006) Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood, 108, pp. 2540-2544.
14. Cheson, B. D. (2003) Radioimmunotherapy of non-Hodgkin lymphomas. Blood, 101, pp. 391-398.
15. Witzig, T. E. (2006) Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Best Pract Res Clin Haematol, 19, pp. 655-668.
16. Gordon, L. I., Molina, A., Witzig, T., Emmanouilides, C., Raubtischek, A. and Darif, M. (2004) Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study. Blood, 103, pp. 4429-4431.
17. Morschhauser, F., Illidge, T., Huglo, D., Martinelli, G., Paganelli, G. and Zinzani, P. L. (2007) Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood, 110, pp. 54-58.
18. Maloney, D. G., Smith, B. and Rose, A. (2002) Rituximab: Mechanism of action and resistance. Semin Oncol, 29, pp. 2-9.
19. Knox, S. J., Levy, R., Miller, R. A., Uhland, W., Schiele, J. and Ruehl, W. (1990) Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Cancer Res, 50, pp. 4935-4940.
20. Skvortsova, I., Skvortsov, S., Popper, B. A., Haidenberger, A., Saurer, M. and Gunkel, A. R. (2006) Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and -independent mechanisms. J Radiat Res, 47, pp. 183-196.
21. Vose, J. M., Wahl, R. L., Saleh, M., Rohatiner, A. Z., Knox, S. J. and Radford, J. A. (2000) Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol, 18, pp. 1316-1323.
22. Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M., Leonard, J. and Fehrenbacher, L. (2001) Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol, 19, pp. 3918-3928.
23. Kaminski, M. S., Tuck, M., Estes, J., Kolstad, A., Ross, C. W. and Zasadny, K. (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med, 352, pp. 441-449.
24. Fisher, R. I., Kaminski, M. S., Wahl, R. L., Knox, S. J., Zelenetz, A. D. and Vose, J. M. (2005) Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol, 23, pp. 7565-7573.
25. Witzig, T. E., Flinn, I. W., Gordon, L. I., Emmanouilides, C., Czuczman, M. S. and Saleh, M. N. (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol, 20, pp. 3262-3269.
26. Wiseman, G. A., Gordon, L. I., Multani, P. S., Witzig, T. E., Spies, S. and Bartlett, N. L. (2002) Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood, 99, pp. 4336-4342.
27. Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C. and Joyce, R. (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol, 20, pp. 2453-2463.
28. Witzig, T. E., Molina, A., Gordon, L. I., Emmanouilides, C., Schilder, R. J. and Flinn, I. W. (2007) Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer, 109, pp. 1804-1810.
29. Liu, S. Y., Eary, J. F., Petersdorf, S. H., Martin, P. J., Maloney, D. G. and Appelbaum, F. R. (1998) Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol, 16, pp. 3270-3278.
30. Gopal, A. K., Rajendran, J. G., Goley, T. A., Pagel, J. M., Fisher, D. R. and Petersdorf, S. (2007) Phase II study of myeloablative I-131 anti CD20 (tositumomab) radioimmunotherapy and autologous hematopoietic stem cell transplantation (ASCT) for adults >60 years of age with high-risk relapsed or refractory B-cell lymphoma. J Clin Oncol, 25, pp. 1396-1402.
31. Flinn, I. W., Kahl, B. S., Frey, E. C., Bianco, J. A., Hammes, R. J. and Webb, J. (2006) Dose finding trial of Yttrium 90 ibritumomab tiuxetan (90YIT0 with autologous stem cell transplantation in patients with relapse or refractory B-cell non-Hodgkin's lymphoma (NHL). J Clin Oncol, 24, p. 7535.
32. Vanazzi, A., Ferrucci, P. F., Grana, C., Cremonesi, M., Clerici, M. and Radice, D. (2006) High dose 90Yttrium ibritumomab tiuxetan (Zevalin) treatment with PBSC support in refractory-resistant NHL patients: A phase I/II study. Blood, 108, p. 2720.
33. Devizzi, L., Seregni, E., Guidetti, A., Fomi, C., Coliva, A. and Magni, M. (2006) High dose myeloablative Zevalin radioimmunotherapy with tandem stem-cell autografting has promising activity, minimal toxicity and full feasibility in an outpatient setting. Blood, 108, p. 3047.
34. Press, O. W., Eary, J. F., Gooley, T., Gopal, A. K., Liu, S. and Rajendran, J. G. (2000) A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood, 96, pp. 2934-2942.
35. Nademanee, A., Krishnan, A. Y., Tsai, N., Palmer, J., Molina, A. and Fung, H. (2006) Yttrium 90 ibritumomab tiuxetan (Zevalin) in combination with high-dose therapy (HDT) followed by autologous stem cell transplant (ASCT) may improve survival in patients with poor-risk follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL): Results of a retrospective comparative analysis. Blood, 108, p. 327.
36. Nademanee, A., Forman, S., Molina, A., Fung, H., Smith, D. and Dagis, A. (2005) A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood, 106, pp. 2896-2902.
37. 90Y ibritumomab tiuxetan (Zevalin) doses calculated to deliver up to 1500 cGy to critical organs may be safely combined with high-dose BEAM and autotransplant in NHL. Blood, 108, p. 330.
38. Vose, J. M., Bierman, P. J., Enke, C., Hankins, J., Bociek, G. and Lynch, J. C. (2005) Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol, 23, pp. 461-467.
39. Krishnan, A. Y., Nademanee, A., Raubitschek, A., Fung, H., Molina, A. and Yamauchi, D. (2006) A comparison of Beam and Yttrium 90 ibritumomab tiuxetan (Zevalin) in addition to Beam (Z-BEAM) in older patients undergoing autologous stem cell transplant (ASCT) for B-cell lymphomas: impact of radioimmunotherapy on transplant outcomes. Blood, 108, p. 3043.
40. Khouri, I. F., Saliba, R. M., Hosing, C., Valverde, R., Erwin, W. D. and Fayad, L. (2006) Efficacy and safety of yttrium 90 (90Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin's lymphoma (NHL). Blood, 108
41. Shimoni, A., Zwas, S. T., Oksman, Y., Hardan, I., Shem-Tov, N. and Yerushalmi, R. (2007) Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp Hematol, 35, pp. 534-540.
42. Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C. and Nelp, W. B. (1993) Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med, 329, pp. 1219-1224.
43. Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Nelp, W. B. and Glenn, S. (1995) Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet, 346, pp. 336-340.
44. Vanazzi, A., Ferrucci, P. F., Ferrari, M., Calabrese, L., Cremonesi, M. and Bartolomei, M. (2005) High dose Zevalin (90Yttrium ibritumomab tiuxetan) treatment with PBSC support in refractory-resistant NHL patients: Preliminary results of a phase I/II study. Blood, 106, p. 488.
45. Gopal, A. K., Gooley, T. A., Maloney, D. G., Petersdorf, S. H., Eary, J. F. and Rajendran, J. G. (2003) High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: A multivariable cohort analysis. Blood, 102, pp. 2351-2357.
46. Winter, J. N. (2004) Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma. Clin Lymphoma, 5, pp. S22-S26.
47. Butcher, B. W. and Collins Jr, R. H. (2005) The graft-versus-lymphoma effect: Clinical review and future opportunities. Bone Marrow Transplant, 36, pp. 1-17.
48. Robinson, S. P., Goldstone, A. H., Mackinnon, S., Carella, A., Russell, N. and de Elvira, C. R. (2002) Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood, 100, pp. 4310-4316.
49. van Besien, K., Sobocinski, K. A., Rowlings, P. A., Murphy, S. C., Armitage, J. O. and Bishop, M. R. (1998) Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood, 91, pp. 1178-1184.
50. Jones, R. J., Ambinder, R. F., Piantadosi, S. and Santos, G. W. (1991) Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood, 77, pp. 649-653.
51. Champlin, R., Khouri, I., Shimoni, A., Gajewski, J., Kornblau, S. and Molldrem, J. (2000) Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol, 111, pp. 18-29.
52. Nagler, A., Slavin, S., Varadi, G., Naparstek, E. and Samuel, S. (2000) Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant, 25, pp. 1021-1028.
53. Khouri, I. F., Keating, M., Korbling, M., Przepiorka, D., Anderlini, P. and O'Brien, S. (1998) Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol, 16, pp. 2817-2824.
54. Escalon, M. P., Champlin, R. E., Saliba, R. M., Acholonu, S. A., Hosing, C. and Fayad, L. (2004) Nonmyeloablative allogeneic hematopoietic transplantation: A promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol, 22, pp. 2419-2423.
55. Baron, F., Maris, M. B., Sandmaier, B. M., Storer, B. E., Sorror, M. and Diaconescu, R. (2005) Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol, 23, pp. 1993-2003.
56. Dean, R. M., Fowler, D. H., Wilson, W. H., Odom, J., Steinberg, S. M. and Chow, C. (2005) Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant, 11, pp. 593-599.
57. Shimoni, A., Zwas, T., Oksman, Y., Hardan, I., Shem-Tov, N. and Yerushalmi, R. (2007) Ibritumomab tiuxetan (Zevalin®) combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with chemo-refractory non-Hodgkin lymphoma. Bone Marrow Transplant, 39, p. 511.
58. Gopal, A. K., Rajendran, J. G., Pagel, J. M., Guthrie, K. A., Maloney, D. G. and Appelbaum, F. R. (2006) A phase ii trial of 90Y-ibritumomab tiuxetan-based reduced intensity allogeneic peripheral blood stem cell (PBSC) transplantation for relapsed CD20+ B-cell non-Hodgkins lymphoma (NHL). Blood, 108
59. Fietz, T., Uharek, L., Gentilini, C., Muessig, A., Rieger, K. and Marinets, O. (2006) Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan. Leuk Lymphoma, 47, pp. 59-63.